Galal Mariam Ahmed, Abdel Jabar Mai, Zhra Mahmoud, Abdel Rahman Anas M, Aljada Ahmad
Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia.
Metabolomics Section, Department of Clinical Genomics, Center for Genome Medicine, King Faisal Specialist Hospital and Research Center (KFSH-RC), Riyadh, 11211, Saudi Arabia.
Anal Chim Acta. 2021 Nov 1;1184:339009. doi: 10.1016/j.aca.2021.339009. Epub 2021 Sep 2.
The identification of unique senescence markers remains challenging. Current hallmarks of senescent cells, including increased senescence-associated β-galactosidase activity, increased levels of cell cycle regulators such as p16, p27, and p53, and altered levels of sirtuins and lamins, are detected commonly by Western blot and immunohistochemistry methods. Mass spectrometry outperforms these conventional quantification methods in terms of high throughput, specificity, and reproducibility.
To develop multiple reaction monitoring-based tandem mass spectrometric senescence assay for simultaneous measuring of p16, p27, p53, p53-β, the seven proteins of the sirtuins family and the four transcript variants of lamins proteins in aging cell model and cancerous cell lines.
Multiple reaction monitoring-tandem mass transitions per protein were developed for each signature peptide(s) and stable isotope-labeled internal standard. The developed assay was validated in a matrix using breast cancer MCF7 cell lines according to the US-FDA guidelines for bioanalytical assays.
The analytes chromatographic peaks were baseline separated and showed linear behavior in a wide dynamic range with r ≥ 0.98. The method for all proteins has passed the inter/intra-day precision and accuracy validation using three levels of quality control samples. The accuracy and the precision for most analytes were 80-120% and ≤20%, respectively. The method's sensitivity for the panels' signature peptides ranged from 1 ng μL to 1 μg mL. Extraction recovery assessed in two quality control levels was >60% for most analytes. This LC-MS-MS validated senescence assay showed reduced lamin A, lamin A△10, lamin A△50, SIRT1, SIRT3, SIRT5, p53, and p16, as well as p53-β induction, are implicated in replicative senescence. Meanwhile, increased lamin C: lamin A ratio was evident and can diagnose breast carcinogenesis. Moreover, in breast cancer metastasis, reduced SIRT2 and p27 and elevated levels of lamin A△50, SIRT5, SIRT7, and p53-β are evident.
LC-MS/MS is a potent alternative tool to the currently available assays. The high throughput method established can study senescence's role in different pathophysiological processes.
识别独特的衰老标志物仍然具有挑战性。衰老细胞的当前特征,包括衰老相关β-半乳糖苷酶活性增加、细胞周期调节因子如p16、p27和p53水平升高以及沉默调节蛋白和核纤层蛋白水平改变,通常通过蛋白质印迹法和免疫组织化学方法检测。质谱分析法在高通量、特异性和可重复性方面优于这些传统定量方法。
开发基于多反应监测的串联质谱衰老检测方法,用于同时测量衰老细胞模型和癌细胞系中的p16、p27、p53、p53-β、沉默调节蛋白家族的七种蛋白质以及核纤层蛋白的四种转录变体。
针对每个特征肽和稳定同位素标记的内标,开发了每种蛋白质的多反应监测串联质谱跃迁。根据美国食品药品监督管理局生物分析检测指南,在乳腺癌MCF7细胞系基质中对开发的检测方法进行验证。
分析物色谱峰基线分离,在宽动态范围内呈线性行为,r≥0.98。使用三个质量控制样品水平,该方法对所有蛋白质均通过了日内/日间精密度和准确度验证。大多数分析物的准确度和精密度分别为80-120%和≤20%。该方法对各检测组特征肽的灵敏度范围为1 ng μL至1 μg mL。在两个质量控制水平评估的提取回收率对于大多数分析物>60%。这种经过液相色谱-串联质谱验证的衰老检测方法表明,核纤层蛋白A、核纤层蛋白A△10、核纤层蛋白A△50、沉默调节蛋白1、沉默调节蛋白3、沉默调节蛋白5、p53和p16水平降低,以及p53-β诱导与复制性衰老有关。同时,核纤层蛋白C与核纤层蛋白A的比例增加明显,可用于诊断乳腺癌发生。此外,在乳腺癌转移中,沉默调节蛋白2和p27水平降低,核纤层蛋白A△50、沉默调节蛋白5、沉默调节蛋白7和p53-β水平升高明显。
液相色谱-串联质谱是现有检测方法的有力替代工具。建立的高通量方法可以研究衰老在不同病理生理过程中的作用。